Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drug development data announced

Boehringer's linagliptin demonstrates reduction of blood glucose in phase III as Novo Nordisk's degludec achieves proof-of-concept at phase II

Boehringer Ingelheim's linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor under investigation as a once-daily oral treatment against type 2 diabetes, achieved clinically meaningful reductions in blood glucose, according to phase III study data presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).

In four multicentre, 24-week, randomised, double-blind trials, linagliptin's blood glucose reductions were significant versus placebo and sustained over the study periods. The compound, which has a primarily non-renal route of excretion, is being investigated as a monotherapy and in combination with metformin, with pioglitazone and with voglibose, which is not licensed in the UK.

Also at the ADA meeting, Novo Nordisk presented phase II proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycaemic control (similar to insulin glargine) when used once-daily or three-times-weekly.

Insulin degludec, a novel insulin molecule with a distinct ultra-long clinical profile, is believed to slow the absorption rate of the insulin into the blood. This leads to a longer profile of action and the possibility of a three-times-weekly dosing regimen in patients with type 2 diabetes. Insulin degludec will now be investigated in the pivotal phase III BEGIN and BOOST trials.

28th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....